Paradigm shift of staging and treatment for early breast cancer in the sentinel lymph node era

Breast Journal

Volumn 12, Issue SUPPL. 2, 2006, Pages

  Leong, Stanley P L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Metastasis; Sentinel nodes

Indexed keywords

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; GENETIC MARKER; HUMAN; LYMPH NODE DISSECTION; MELANOMA; METASTASIS; MICROMETASTASIS; ONCOLOGY; OUTCOME ASSESSMENT; SENTINEL LYMPH NODE; TUMOR VOLUME;

BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; TUMOR MARKERS, BIOLOGICAL;

EID: 33748361363     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2006.00326.x     Document Type: Article

References (64)

1. Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996;131:301-8.
2. Andersen LD, Remington P, Trentham-Dietz A, Reeves M. Assessing a decade of progress in cancer control. Oncologist 2002;7:200-204.
3. Begg CB. The mammography controversy. Oncologist 2002;7:174-76.
4. Tabar L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin N Am 2000;38:625-51.
5. Ibarra JA. The pathologist in breast cancer: contemporary issues in the interdisciplinary approach. Surg Oncol Clin N Am 2000;9:295-317.
6. Nemoto T, Vana J, Bedwani RN, McGregor FN, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980;45:2917-24.
7. Arnesson LG, Smeds S, Fagerberg G. Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening. Eur J Surg 1994;160:271-76.
8. Wood WC, Anderson M, Lyles RH, et al. Can we select which patients with small breast cancers should receive adjuvant chemotherapy? Ann Surg 2002;235:859-62.
9. Niederhuber JE. Seeking calmer waters in a sea of controversy. Oncologist 2002;7:172-73.
10. Von Eschenbach AC. NCI remains committed to current mammography guidelines. Oncologist 2002;7:170-71.
11. Chung MA, Cady B. New lessons from the sentinel node. Surg Oncol Clin N Am 2001;10:461-73, xi-xii.
12. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46:1.
13. Keynes G. Carcinoma of the breast, the unorthodox view. Proc Cardiff M Soc 1954:40.
14. Crile G Jr. Biological Consideration of the Treatment of Breast Cancer. Springfield, IL: Charles C. Thomas, 1967.
15. Fisher B. Laboratory and clinical research in breast cancer - a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 1980;40:3863-74.
16. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-81.
17. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.
18. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
19. Hellman S. The natural history of small breast cancers: the David A. Karnovsky Memorial Lecture. J Clin Oncol 1994;12:2229-34.
20. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10.
21. Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat 1985;5:17-21.
22. Adjuvant therapy for breast cancer. NIH Consens Statement 2000;17:1-35.
23. Seaman W, Powers W. Studies on the distribution of radioactive colloidal gold in regional lymph nodes containing cancer. Cancer 1955;8:1044-46.
24. Gould EA, Winship T, Pholbin PH, Hyland Kerr H. Observations on a "sentinel node" in cancer of the parotid. Cancer 1960;13:77-78.
25. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-66.
26. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg 1991;214:637-41.
27. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-99.
28. Reintgen DS, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.
29. Leong SPL. Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol 2004;11(3 suppl):192S-97S.
30. Leong SPL, Morita ET, Treseler PA, Wong JH. Multidisciplinary approach to selective sentinel lymph node mapping in breast cancer. Breast Cancer 2000;7:105-13.
31. Leong SPL. Selective sentinel lymphadenectomy for breast cancer in the United States. Asian J Surg 2004;27:268-74.
32. Leong SPL. Selective sentinel lymphadenectomy for malignant melanoma. Surg Clin N Am 2003;83:157-85, vii.
33. Leong SPL, Wong JH. Sentinel Lymph Nodes in Human Solid Cancer. Philadelphia: W.B. Saunders, 2000.
34. Borgstein P, Meijer S. Historical perspective of lymphatic tumour spread and the emergence of the sentinel node concept. Eur J Surg Oncol 1998;24:85-89.
35. Leong SPL, Kitagawa Y, Kitajima M. Selective Sentinel Lymphadenectomy for Human Solid Cancer. New York: Springer, 2005.
36. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
37. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-60.
38. Cody HS 3rd. Sentinel lymph node mapping in breast cancer. Oncology 1999;13:25-34; discussion 5-6, 9, 43.
39. Carpenter R. Sentinel node biopsy should be introduced into routine practice before results of randomized trials are available. Breast 2001;10:281-84.
40. Huvos AG, Hutter RV, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971;173:44-46.
41. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW. Axillary micro- and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg 1981;194:585-91.
42. Rosen PP, Saigo PE, Braun DW, Weathers E, Kinne DW. Prognosis in stage II (T1N1M0) breast cancer. Ann Surg 1981;194:576-84.
43. Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Cancer 1993;71:1780-90.
44. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17: intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer 1995;75:1310-19.
45. Byrne J, Horgan PG, England S, Callaghan J, Given HF. A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma. Eur J Cancer 1992;28:658-60.
46. Chen ZL, Wen DR, Coulson WF, Giuliano AE, Cochran AJ. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology. Dis Markers 1991;9:239-48.
47. Cote R, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999;354:896-900.
48. Sedmak DD, Meineke TA, Knechtges DS, Anderson J. Prognostic significance of cytokeratin-positive breast cancer metastases. Mod Pathol 1989;2:516-20.
49. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303-6.
50. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992;66:523-27.
51. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993;80:459-63.
52. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996;73:88-95.
53. Nasser IA, Lee AKC, Bosari S, et al. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum Pathol 1993;24:950-57.
54. Colleoni M, Rotmensz N, Peruzzotti G, et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 2005;23:1379-89.
55. Braun S, Cevatli BS, Assemi C, et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001;19:1468-75.
56. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-99; discussion 399-401.
57. Cox CE, Salud CJ, Harrinton MA. The role of selective sentinel lymph node dissection in breast cancer. Surg Clin N Am 2000;80:1759-77.
58. Chen M, Palleschi S, Khoynezhad A, Gecelter G, Marini CP, Simms HH. Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis. Arch Surg 2002;137:606-9; discussion 609-10.
59. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
60. American Joint Committee on Cancer. Cancer Staging Manual, 6th ed. New York: Springer, 2003.
61. Tan YY, Wu CT, Fan YG, et al. Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer. Breast J 2005;11:338-43.
62. Tan YY, Fan YG, Lu Y, et al. Ratio of positive to total number of sentinel nodes predicts nonsentinel node status in breast cancer patients. Breast J 2005;11:248-53.
63. Fan YG, Tan YY, Wu CT, et al. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer. Ann Surg Oncol 2005;12:705-11.
64. Harris JR, Henderson CI. Natural history and staging of breast cancer. In: Harris JR, Henderson CI, Hellman S, Kinne DW, eds. Breast Diseases. Philadelphia: Lippincott, 1987:233-58.